Insight Molecular Diagnostics
Insight Molecular Diagnostics' revenue rose 115.6% to $4 million in fiscal 2025. Its operating margin was −1,260.8%, up from −3,245.1% a year earlier. Free cash flow was −$25 million. The diluted share count rose 133.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Insight Molecular Diagnostics lost money in fiscal 2025: a net loss of $50 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 33 | 20 | 9 | 9 | 12 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −471.3x | −749.9x | −3,590.9x | −1,453.4x | −561.8x |
| Current ratio | 2.8x | 2.1x | 1.5x | 1.6x | 1.3x |
| Quick ratio | 2.8x | 2.1x | 1.5x | 1.6x | 1.2x |
Cash flow
Projections
Project Insight Molecular Diagnostics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Insight Molecular Diagnostics says to expect
- Fourth quarter 2026: outgoing free cash flow
We continue to target outgoing free cash flow of approximately $8 million in the fourth quarter.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $11.7 million of Insight Molecular Diagnostics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Broadwood Partners L.p.10% owner | Bought | 3,428,571 | $1.75 | $6.0 million | Form 4 |
| Apr 27, 2026 | Broadwood Partners L.p.10% owner | Bought | 250,923 | $3.64 | $913,360 | Form 4 |
| Apr 24, 2026 | Broadwood Partners L.p.10% owner | Bought | 38,880 | $3.53 | $137,246 | Form 4 |
| Apr 23, 2026 | Broadwood Partners L.p.10% owner | Bought | 280,381 | $3.50 | $981,334 | Form 4 |
| Apr 20, 2026 | Broadwood Capital Inc10% owner | Bought | 40,690 | $3.88 | $157,877 | Form 4 |
| Apr 17, 2026 | Broadwood Capital Inc10% owner | Bought | 40,114 | $3.57 | $143,207 | Form 4 |
| Apr 16, 2026 | Broadwood Capital Inc10% owner | Bought | 102,057 | $3.45 | $352,097 | Form 4 |
| Feb 10, 2026 | Neal C Bradsher10% owner | Bought | 521,739 | $5.75 | $3.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −1,513.7% | −1,102.2% | −510.1% |
| Altman Z'' | −14.13 | −43.70 | −63.82 |
| Accruals ratio | −5.1% | −72.7% | −92.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Insight Molecular Diagnostics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics | FY25 | 115.6% | −1,260.8% | −625.6% | — | — | — | |
| VolitionRx | FY25 | 40.0% | −1,258.5% | −1,144.7% | — | — | 2 | Compare |
| ImmuCell | FY25 | 4.3% | 6.0% | 4.4% | — | 1.2x | — | Compare |
| Alpha Pro Tech | FY25 | 2.2% | 6.5% | 2.9% | — | — | — | Compare |
| RxSight | FY25 | −3.9% | −35.8% | −14.4% | −82.9% | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | 1 | 2 | 1 | 2 | 2 | 4 |
| Revenue growth | — | — | — | — | — | 80.8% | −56.4% | 56.9% | 25.1% | 115.6% |
| Gross profit | — | — | — | — | −1 | 1 | −0 | 0 | 1 | 2 |
| Research and development | 6 | 7 | 6 | 7 | 10 | 5 | 7 | 9 | 10 | 16 |
| Operating income | −11 | −19 | −15 | −22 | −30 | −54 | −18 | −25 | −61 | −51 |
| Net income | −11 | −19 | −16 | −22 | −30 | −64 | −73 | −28 | −61 | −50 |
| Diluted EPS (US$) | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −13.25 | −3.75 | −4.66 | −1.65 |
| Diluted shares (millions) | 1,326 | 1,510 | 1,892 | 2,565 | 3 | 4,446 | 6 | 8 | 13 | 30 |
| Cash flow | ||||||||||
| Cash from operations | −8 | −13 | −12 | −20 | −26 | −36 | −46 | −23 | −21 | −22 |
| Capital expenditure | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 0 | 0 | 3 |
| Free cash flow | −8 | −13 | −12 | −21 | −27 | −38 | −50 | −24 | −21 | −25 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 2 | 3 | 5 | 7 | 10 | 3 | 2 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 10 | 8 | 8 | 22 | 7 | 33 | 20 | 9 | 9 | 12 |
| Debt incl. finance leases | — | 2 | — | — | — | — | — | — | — | — |
| Total assets | 14 | 10 | 10 | 40 | 55 | 160 | 100 | 75 | 35 | 26 |
| Total liabilities | 5 | 6 | 6 | 9 | 22 | 94 | 60 | 49 | 47 | 57 |
| Shareholders' equity | 10 | 4 | 3 | 31 | 34 | 65 | 34 | 20 | −12 | −32 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | −52.5% | 64.6% | −1.9% | 27.5% | 39.3% | 56.7% |
| Operating margin | — | — | — | — | −2,443.3% | −2,444.3% | −1,878.6% | −1,672.4% | −3,245.1% | −1,260.8% |
| Net margin | — | — | — | — | −2,461.5% | −2,916.2% | −7,609.8% | −1,848.4% | −3,225.0% | −1,238.5% |
| Free cash flow margin | — | — | — | — | −2,237.4% | −1,737.4% | −5,209.6% | −1,570.6% | −1,127.3% | −625.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −1,656.6% | −5,266.0% | −1,513.7% | −1,102.2% | −510.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −110.1% | −271.6% | −402.6% | −130.9% | −93.1% | −129.9% | −146.5% | −101.5% | −1,480.7% | — |
| Return on assets | −82.2% | −157.1% | −159.7% | −90.8% | −62.8% | −59.6% | −56.1% | −31.8% | −110.3% | −165.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |